Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

5 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Neurological Examination Week 38 Mepolizumab HES NCT00086658 - Neurological Examination Week 38

- 15/7/17 - 1 formulario, 1 itemgroup, 18 items, 1 idioma
Itemgroup: Neurological Examination
Study part: Neurological Examination Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 16 Mepolizumab HES NCT00086658 - Neurological Examination Week 16

- 12/7/17 - 1 formulario, 1 itemgroup, 18 items, 1 idioma
Itemgroup: Neurological Examination
Study part: Neurological Examination Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 8 Mepolizumab HES NCT00086658 - Neurological Examination Week 8

- 9/7/17 - 1 formulario, 1 itemgroup, 18 items, 1 idioma
Itemgroup: Neurological Examination
Study part: Neurological Examination Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 4 Mepolizumab HES NCT00086658 - Neurological Examination Week 4

- 11/6/17 - 1 formulario, 1 itemgroup, 18 items, 1 idioma
Itemgroup: Neurological Examination
Study part: Neurological Examination Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Neurological Examination Day 1 Pre-Infusion

- 11/6/17 - 1 formulario, 1 itemgroup, 18 items, 1 idioma
Itemgroup: Neurological Examination
Study part: Neurological Examination Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial